Integrating toxicogenomics into human health risk assessment: Lessons learned from the benzo[a]pyrene case study

References

• Allen BC, Strong PL, Price CJ, Hubbard SA, Daston GP. (1996). Benchmark dose analysis of developmental toxicity in rats exposed to boric acid. Fundam Appl Toxicol, 32, 194–204.
   PubMedGoogle Scholar
• Auerbach SS, Shah RR, Mav D, Smith CS, Walker NJ Vallant MK, et al. (2010). Predicting the hepatocarcinogenic potential of alkenylbenzene flavoring agents using toxicogenomics and machine learning. Toxicol Appl Pharmacol 243:300–314.
   PubMed Web of Science ®Google Scholar
• Black MB, Parks BB, Pluta L, Chu TM, Allen BC, Wolfinger RD, Thomas RS, et al. (2014). Comparison of microarrays and RNA-seq for gene expression analyses of dose-response experiments. Toxicol Sci, 137, 385–403.
   PubMed Web of Science ®Google Scholar
• Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C et al. (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Crit Rev Toxicol 36:781–792.
   PubMed Web of Science ®Google Scholar
• Bourdon JA, Williams A, Kuo B, Moffat I, White PA, Halappanavar S, et al. (2013). Gene expression profiling to identify potentially relevant disease outcomes and support human health risk assessment for carbon black nanoparticle exposure. Toxicology, 303C, 83–93.
   Google Scholar
• Daston GP, Naciff JM. (2010). Predicting developmental toxicity through toxicogenomics. Birth Defects Res C Embryo Today, 90, 110–7.
   PubMed Web of Science ®Google Scholar
• Elferink MG, Olinga P, Draaisma AL, Merema MT, Bauerschmidt S, Polman J, et al. (2008). Microarray analysis in rat liver slices correctly predicts in vivo hepatotoxicity. Toxicol Appl Pharmacol, 229, 300–9.
   PubMed Web of Science ®Google Scholar
• Gold LS, Manley NB, Slone TH, Ward JM. (2001). Compendium of chemical carcinogens by target organ: results of chronic bioassays in rats, mice, hamsters, dogs, and monkeys. Toxicol Pathol, 29, 639–52.
   PubMed Web of Science ®Google Scholar
• Goodsaid FM, Amur S, Aubrecht J, Burczynski ME, Carl K, Catalano J, et al. (2010). Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact. Nat Rev Drug Discov 9, 435–445.
   PubMed Web of Science ®Google Scholar
• Hill A. (1965). THE ENVIRONMENT AND DISEASE: ASSOCIATION OR CAUSATION?. Proc R Soc Med 58:295–300.
   PubMed Web of Science ®Google Scholar
• IARC (International Agency for Research on Cancer). (2012). A review of human carcinogens: Chemical agents and related occupations. IARC Monogr Eval Carcinog Risks Hum 100F, 111–44 .
   Google Scholar
• Jackson AF, Williams A, Recio L, Waters MD, Lambert IB, Yauk CL. (2014). Case study on the utility of hepatic global gene expression profiling in the risk assessment of the carcinogen furan. Toxicol Appl Pharmacol, 274, 63–77.
   PubMed Web of Science ®Google Scholar
• Lemieux C, Douglas G, Gingerich J, Phonethepswath S, Torous DK, Dertinger SD, et al. (2011). Simultaneous measurement of benzo[a]pyrene-induced Pig-a and lacZ mutations, micronuclei and DNA adducts in Muta™(Mouse. Environ Mol Mutagen, 52, 756–65.
   PubMed Web of Science ®Google Scholar
• Li H, Qiu J, Fu XD. (2012). RASL-seq for massively parallel and quantitative analysis of gene expression. Curr. Protoc. Mol. Biol. 98:4.13.1–4.13.9.
   Google Scholar
• Li H-H, Hyduke DR, Chen R, Heard P, Aubrecht J, Fornace AJ Jr. (2014). Development of a toxicogenomics signature for genotoxicity using a dose-optimization and informatics strategy in human cells. (submitted to Toxicol. Sci.) xxx–xxx.
   Google Scholar
• Lin WJ, Hsueh HM, Chen JJ. (2010). Power and sample size estimation in microarray studies. BMC Bioinformatics, 11, 48.
   PubMed Web of Science ®Google Scholar
• Lobenhofer EK, Cui X, Bennett L, Cable PL, Merrick BA, Churchill GA, Afshari CA, et al.(2004). Exploration of low-dose estrogen effects: Identification of No Observed Transcriptional Effect Level (NOTEL). Toxicol Pathol, 32, 482–92.
   PubMed Web of Science ®Google Scholar
• Mathijs K, Brauers KJ, Jennen DG, Boorsma A, van Herwijnen MH, Gottschalk RW, et al. (2009). Discrimination for genotoxic and nongenotoxic carcinogens by gene expression profiling in primary mouse hepatocytes improves with exposure time. Toxicol Sci., 112, 374–84.
   PubMed Web of Science ®Google Scholar
• Meek ME. (2008). Recent developments in frameworks to consider human relevance of hypothesized modes of action for tumours in animals. Environ Mol Mutagen, 49, 110–6.
   PubMed Web of Science ®Google Scholar
• Meek ME, Klaunig JE. (2010). Proposed mode of action of benzene-induced leukemia: Interpreting available data and identifying critical data gaps for risk assessment. Chem Biol Interact, 184, 279–85.
   PubMed Web of Science ®Google Scholar
• Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, et al. (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Crit Rev Toxicol, 33, 591–653.
   PubMed Web of Science ®Google Scholar
• Meek ME, Palermo CM, Bachman AN, North CM, Jeffrey Lewis R. (2014). Mode of action human relevance (species concordance) framework: Eevolution of the Bradford Hill considerations and comparative analysis of weight of evidence. J Appl Toxicol 34(6): 595–606.
   PubMed Web of Science ®Google Scholar
• Moffat ID, Chepelev NL, Labib S, Bourdon-Lacombe J, Kuo B, Buick JK. et al. (2014). Comparison of toxicogenomics and traditional approaches in quantitative risk assessment of benzo(a)pyrene for drinking water. Crit Rev Toxicol 45, 1–43.
   Google Scholar
• NRC (National Research Council). (2007b). Toxicity Testing in the 21st Century: A Vision and a Strategy. Washington, DC: The National Academies Press.
   Google Scholar
• OECD. (Organisation for Economic Co-operation and Development). (2012a). Guidance document 116 on the conduct and design of chronic toxicity and carcinogenicity studies, supporting test guidelines 451, 452 and 453. 2nd edition. Available at from: http://search.oecd.org/officialdocuments/displaydocumentpdf/?cote = ENV/JM/MONO(2011)47&doclanguage = en. Accessed on August August 1, 2013.
   Google Scholar
• OECD. (2012b). Proposal for a template, and guidance on developing and assessing the completeness of adverse outcome pathways. Available from: http://www.oecd.org/env/ehs/testing/49963554.pdf. Accessed on August 12, 2013.
   Google Scholar
• Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, et al. (2006). The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements. Nat Biotechnol, 24, 1151–61.
   PubMed Web of Science ®Google Scholar
• Sonich-Mullin C, Fielder R, Wiltse J, Baetcke K, Dempsey J, Fenner-Crisp P, et al. (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regul Toxicol Pharmacol 34, 146–52.
   PubMed Web of Science ®Google Scholar
• Steinhoff C, Vingron M. (2006). Normalization and quantification of differential expression in gene expression microarrays. Brief Bioinform, 7, 166–77.
   PubMed Web of Science ®Google Scholar
• Thomas RS, Clewell HJ III, Allen BC, Yang L, Healy E, Andersen ME, et al. (2012). Integrating pathway-based transcriptomic data into quantitative chemical risk assessment: A five chemical case study. Mutat Res, 746, 135–43.
   PubMed Web of Science ®Google Scholar
• Thomas RS, Allen BC, Nong A, Yang L, Bermudez E, Clewell HJ III, Andersen ME, et al. (2007). A method to integrate benchmark dose estimates with genomic data to assess the functional effects of chemical exposure. Toxicol Sci., 98, 240–28.
   PubMed Web of Science ®Google Scholar
• Thomas RS, Clewell HJ III, Allen BC, Wesselkamper SC, Wang NC, Lambert JC, et al. (2011). Application of transcriptional benchmark dose values in quantitative cancer and noncancer risk assessment. Toxicol Sci., 120, 194–205.
   PubMed Web of Science ®Google Scholar
• Thomas RS, Philbert MA, Auerbach SS, Wetmore BA, Devito MJ, Cote I, et al. (2013). Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci., 136, 4–18.
   PubMed Web of Science ®Google Scholar
• US EPA. (2012). Benchmark dose technical guidance 2012. Available from: http://www.epa.gov/osa/raf/publications/benchmark_dose_guidance.pdf. Accessed on August 28, 2013.
   Google Scholar
• US EPA. (2005). Guidelines for carcinogen risk assessment 2012. Available from: http://www.epa.gov/cancerguidelines/. Accessed on August 28, 2013.
   Google Scholar
• US EPA (2011). Integrated Risk Information System (IRIS) Glossary. Available from: http://www.epa.gov/ncea/iris/index.html. Accessed on May 13, 2014.
   Google Scholar
• van Delft JH, Mathijs K, Staal YC, van Herwijnen MH, Brauers KJ, Boorsma A, Kleinjans JC, et al. (2010). Time series analysis of benzo[A]pyrene-induced transcriptome changes suggests that a network of transcription factors regulates the effects on functional gene sets. Toxicol Sci., 117, 381–92.
   PubMed Web of Science ®Google Scholar
• Wang Y, Barbacioru C, Hyland F, Xiao W, Hunkapiller KL, Blake J, et al. (2006). Large scale real-time PCR validation on gene expression measurements from two commercial long-oligonucleotide microarrays. BMC Genomics, 7, 59.
   PubMed Web of Science ®Google Scholar
• Yauk CL, Berndt ML. (2007). Review of the literature examining the correlation among DNA microarray technologies. Environ Mol Mutagen, 48, 380–94.
   PubMed Web of Science ®Google Scholar
• Yauk CL, Bishop J, Dearfield KL, Douglas GR, Hales BF, Luijten M, et al. (2013). The development of adverse outcome pathways for mutagenic effects for the organization for economic co-operation and development. Environ Mol Mutagen, 54, 79–81.
   PubMed Web of Science ®Google Scholar